CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Man, Xiao Yong ^a   Finnson, Kenneth W ^a   Baron, Murray ^b   Philip, Anie ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD109 PROTEIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; CD109 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SKIN FIBROBLAST; WESTERN BLOTTING; AGED; CYTOLOGY; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN; SYSTEMIC SCLEROSIS; UPREGULATION;

ADULT; AGED; ANTIGENS, CD; BLOTTING, WESTERN; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84862209561     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3877     Document Type: Article

References (54)

1. Wick G, Backovic A, Rabensteiner E, Plank N, Schwendtner C, Sgonc R. The immunology of fibrosis: innate and adaptive responses. Trends Immunol 2010, 31:110-119. 10.1016/j.it.2009.12.001, 3292796, 20106721.
2. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010, 152:159-166.
3. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 2010, 14:1241-1254. 10.1111/j.1582-4934.2010.01027.x, 20132409.
4. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011, 40:78-83. 10.1007/s12016-010-8198-y, 20143182.
5. Varga J, Pasche B. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009, 5:200-206. 10.1038/nrrheum.2009.26, 19337284.
6. Szodoray P, Kiss E. Progressive systemic sclerosis - from the molecular background to innovative therapies. Front Biosci (Elite Ed) 2010, 2:521-525.
7. Smith G, Chan E. Molecular pathogenesis of skin fibrosis: insight from animal models. Curr Rheumatol Rep 2010, 12:26-33. 10.1007/s11926-009-0080-7, 2861786, 20425530.
8. Postlethwaite AE, Harris LJ, Raza SH, Kodura S, Akhigbe T. Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother 2010, 11:789-806. 10.1517/14656561003592177, 2837533, 20210685.
9. Asano Y. Future treatments in systemic sclerosis. J Dermatol 2010, 37:54-70. 10.1111/j.1346-8138.2009.00758.x, 20175840.
10. Wu MY, Hill CS. TGF-β superfamily signaling in embryonic development and homeostasis. Dev Cell 2009, 16:329-343. 10.1016/j.devcel.2009.02.012, 19289080.
11. Wharton K, Derynck R. TGF-β family signaling: novel insights in development and disease. Development 2009, 136:3691-3697. 10.1242/dev.040584, 19855012.
12. Moustakas A, Heldin CH. The regulation of TGFβ signal transduction. Development 2009, 136:3699-3714. 10.1242/dev.030338, 19855013.
13. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010, 37:11-25. 10.1111/j.1346-8138.2009.00738.x, 20175837.
14. Varga J, Whitfield ML. Transforming growth factor-β in systemic sclerosis (scleroderma). Front Biosci (Schol Ed) 2009, 1:226-235.
15. Ihn H. Autocrine TGF-β signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008, 49:103-113. 10.1016/j.jdermsci.2007.05.014, 17628443.
16. Pannu J, Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 2004, 16:739-745. 10.1097/01.bor.0000137894.63091.1a, 15577613.
17. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001, 44:474-480. 10.1002/1529-0131(200102)44:2<474::AID-ANR67>3.0.CO;2-#, 11229480.
18. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998, 110:47-51. 10.1046/j.1523-1747.1998.00073.x, 9424086.
19. Kubo M, Ihn H, Yamane K, Tamaki K. Upregulated expression of transforming growth factor-β receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol 2002, 29:2558-2564.
20. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, ten Dijke P, White B, Wigley FM, Goldschmidt-Clermont PJ. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002, 99:3908-3913. 10.1073/pnas.062010399, 122622, 11904440.
21. Pannu J, Gore-Hyer E, Yamanaka M, Smith EA, Rubinchik S, Dong JY, Jablonska S, Blaszczyk M, Trojanowska M. An increased transforming growth factor β receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma. Arthritis Rheum 2004, 50:1566-1577. 10.1002/art.20225, 15146427.
22. Thatcher JD. The TGF-β signal transduction pathway. Sci Signal 2010, 3:tr4. 10.1126/scisignal.3119tr4, 20424268.
23. Massague J, Gomis RR. The logic of TGF-β signaling. FEBS Lett 2006, 580:2811-2820. 10.1016/j.febslet.2006.04.033, 16678165.
24. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003, 113:685-700. 10.1016/S0092-8674(03)00432-X, 12809600.
25. Schmierer B, Hill CS. TGFβ-Smad signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007, 8:970-982. 10.1038/nrm2297, 18000526.
26. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008, 40:383-408. 10.1016/j.biocel.2007.09.006, 18061509.
27. Leask A. Targeting the TGFβ, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 2008, 20:1409-1414. 10.1016/j.cellsig.2008.01.006, 18296024.
28. Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R, Wu X-F, Schuh AC. Cell surface antigen CD109 is a novel member of the alpha 2 macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 2002, 99:1683-1691. 10.1182/blood.V99.5.1683, 11861284.
29. Solomon KR, Sharma P, Chan M, Morrison PT, Finberg RW. CD109 represents a novel branch of the α2-macroglobulin/complement gene family. Gene 2004, 327:171-183. 10.1016/j.gene.2003.11.025, 14980714.
30. Hagiwara S, Murakumo Y, Mii S, Shigetomi T, Yamamoto N, Furue H, Ueda M, Takahashi M. Processing of CD109 by furin and its role in the regulation of TGF-β signaling. Oncogene 2010, 29:2181-2191. 10.1038/onc.2009.506, 20101215.
31. Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, Inoue Y, Ihn H, Matsumoto Y, Kato M. CD109 expression levels in malignant melanoma. J Dermatol Sci 2009, 57:140-142.
32. Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat 2009, 124:27-38. 2929293, 20035377.
33. Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C, Mii S, Jijiwa M, Enomoto A, Asai N, Ishihara S, Takahashi M. CD109 expression in basal-like breast carcinoma. Pathol Int 2008, 58:288-294. 10.1111/j.1440-1827.2008.02225.x, 18429827.
34. Hagiwara S, Murakumo Y, Sato T, Shigetom T, Mitsudo K, Tohnai I, Ueda M, Takahashi M. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 2008, 99:1916-1923.
35. Hasegawa M, Hagiwara S, Sato T, Jijiwa M, Murakumo Y, Maeda M, Moritani S, Ichihara S, Takahashi M. CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int 2007, 57:245-250. 10.1111/j.1440-1827.2007.02097.x, 17493171.
36. Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, Finnson KW, Buschmann MD, Philip A. The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors. Biochim Biophys Acta Mol Cell Res 2011, 1813:742-753.
37. Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, Bizet AA, Philip A. Identification of CD109 as part of the TGF-β receptor system in human keratinocytes. FASEB J 2006, 20:1525-1527. 10.1096/fj.05-5229fje, 16754747.
38. Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, Choquette D, Raymond Y, Senecal JL. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001, 44:735-736. 10.1002/1529-0131(200103)44:3<735::AID-ANR125>3.0.CO;2-F, 11263791.
39. Tam B, Germain L, Philip A. TGF-β receptor expression on human keratinocytes: a 150 kDa GPI-anchored TGF-β1 binding protein forms a heteromeric complex with type I and type II receptors. J Cell Biochem 1998, 70:573-586. 10.1002/(SICI)1097-4644(19980915)70:4<573::AID-JCB13>3.0.CO;2-I, 9712154.
40. Tam BYY, Finnson KW, Philip A. Glycosylphosphatidylinositol-anchored proteins regulate transforming growth factor-β signaling in human keratinocytes. J Biol Chem 2003, 278:49610-49617. 10.1074/jbc.M308492200, 14504277.
41. Tam B, Philip A. Transforming growth factor-β receptor expression on human skin fibroblasts: dimeric complex formation of type I and type II receptors and identification of glycosyl phosphatidylinositol-anchored transforming growth factor-β binding proteins. J Cell Physiol 1998, 176:553-564. 10.1002/(SICI)1097-4652(199809)176:3<553::AID-JCP12>3.0.CO;2-0, 9699508.
42. Tam B, Larouche D, Germain L, Hooper N, Philip A. Characterization of a 150 kDa accessory receptor for TGF-β1 on keratinocytes: direct evidence for a GPI anchor and ligand binding of the released form. J Cell Biochem 2001, 83:494-507. 10.1002/jcb.1074, 11596117.
43. Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford) 2006, 45:157-165.
44. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004, 113:253-264. 310747, 14722617.
45. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML. A TGFβ-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010, 130:694-705. 10.1038/jid.2009.318, 19812599.
46. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, Whitfield ML. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008, 3:e2696. 10.1371/journal.pone.0002696, 2481301, 18648520.
47. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, Chen Y, Venstrom K, Dou X, Ponticos M, Black C, Bernabeu C, Jackman JK, Findell PR, Conolly MK. Dysregulation of transforming growth factor β signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002, 46:1857-1865. 10.1002/art.10333, 12124870.
48. Morris E, Chrobak I, Bujor A, Hant F, Mummery C, Ten Dijke P, Trojanowska M. Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 2011, 226:3340-3348. 10.1002/jcp.22690, 21344387.
49. Holmes AM, Ponticos M, Shi-Wen X, Denton CP, Abraham DJ. Elevated CCN2 expression in scleroderma: a putative role for the TGF-β accessory receptors TGFβRIII and endoglin. J Cell Commun Signal 2011, 5:173-177. 10.1007/s12079-011-0140-4, 3145876, 21769684.
50. Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001, 44:731-734. 10.1002/1529-0131(200103)44:3<731::AID-ANR124>3.0.CO;2-U, 11263790.
51. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, Lafyatis R. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS ONE 2010, 5.
52. Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y, Takahashi M. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 2007, 57:719-724. 10.1111/j.1440-1827.2007.02168.x, 17922683.
53. Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M, Nakamura S, Takahashi M. CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 2005, 55:165-169. 10.1111/j.1440-1827.2005.01807.x, 15826242.
54. Furst DE, Clements PJ, Steen VD, Medsger TA, Masi AT, D'Angelo WA, Lachenbruch PA, Grau RG, Seibold JR. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998, 25:84-88.